Kyongbo Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Kyongbo Pharmaceutical has a total shareholder equity of ₩144.4B and total debt of ₩73.2B, which brings its debt-to-equity ratio to 50.7%. Its total assets and total liabilities are ₩266.3B and ₩121.9B respectively. Kyongbo Pharmaceutical's EBIT is ₩5.5B making its interest coverage ratio 1.7. It has cash and short-term investments of ₩5.3B.
Key information
50.7%
Debt to equity ratio
₩73.23b
Debt
| Interest coverage ratio | 1.7x |
| Cash | ₩5.35b |
| Equity | ₩144.38b |
| Total liabilities | ₩121.92b |
| Total assets | ₩266.31b |
Recent financial health updates
Kyongbo Pharmaceutical (KRX:214390) Has A Somewhat Strained Balance Sheet
Mar 09
Is Kyongbo Pharmaceutical (KRX:214390) A Risky Investment?
Dec 08
Recent updates
Kyongbo Pharmaceutical (KRX:214390) Has A Somewhat Strained Balance Sheet
Mar 09What Type Of Shareholders Own The Most Number of Kyongbo Pharmaceutical Co., Ltd (KRX:214390) Shares?
Feb 02Kyongbo Pharmaceutical Co., Ltd's (KRX:214390) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Jan 12Did You Miss Kyongbo Pharmaceutical's (KRX:214390) Impressive 107% Share Price Gain?
Dec 25Is Kyongbo Pharmaceutical (KRX:214390) A Risky Investment?
Dec 08Does Kyongbo Pharmaceutical's (KRX:214390) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 18Financial Position Analysis
Short Term Liabilities: A214390's short term assets (₩135.9B) exceed its short term liabilities (₩118.3B).
Long Term Liabilities: A214390's short term assets (₩135.9B) exceed its long term liabilities (₩3.7B).
Debt to Equity History and Analysis
Debt Level: A214390's net debt to equity ratio (47%) is considered high.
Reducing Debt: A214390's debt to equity ratio has increased from 28.6% to 50.7% over the past 5 years.
Debt Coverage: A214390's debt is not well covered by operating cash flow (6.6%).
Interest Coverage: A214390's interest payments on its debt are not well covered by EBIT (1.7x coverage).